Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases
Inflamm. Bowel Dis. 2020 Jul 17;26(8)1232-1238, EM Kim, C Randall, R Betancourt, S Keene, A Lilly, M Fowler, ES Dellon, HH HerfarthFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.